Waskyra
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Waskyra, covering 2025-11-14 to 2026-03-05. Get the full timeline:
Most recent: EMA Authorised: Waskyra (genetically modified autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human Wiskott-Aldrich Syndrome (WAS) gene) — Fondazione Telethon ETS